In today’s briefing:
- Prodia (PRDA IJ) – A Standout in Diagnostics
- Bloomberry Resorts Corp: 3Q22 Revenue Surge Reinforces Our Strong Buy Guidance
Prodia (PRDA IJ) – A Standout in Diagnostics
- Prodia (PRDA IJ) is a stand out amongst Indonesia’s healthcare players given it is the only company in Indonesia with accreditation from the College of American Pathologists.
- 3Q2022 reflected a normalisation of the testing business towards routine testing but at higher levels, and with a greater variety of tests with more advanced levels of digitalisation.
- Prodia (PRDA IJ) stands out in terms of its strong market positioning and track record together with attractive valuations, especially versus Indian peers in the diagnostic space.
Bloomberry Resorts Corp: 3Q22 Revenue Surge Reinforces Our Strong Buy Guidance
- While Macau remains hostage to Beijing’s zero tolerance covid policy, Philippine gaming has taken the lead in ASEAN recovery ramp.
- The Soliare property at manila has outperformed expectations on the basis of pent up demand beginning to show in domestic player revenue.
- CEO Razon has confirmed continuing expansion plans at Cebu and Emerald Bay to be completed before the end of 2023. Both will be accretive to group EBITDA.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
